← Analysis page  ·  Nomi Prins hub  ·  Research hub

Actionable insights — The Tungsten Producer Poised to Benefit From the Squeeze

The repeatable analysis behind the pick: not that she bought Almonty, but how to isolate the single company that captures a critical-metal chokepoint — the integration test, the locked-offtake test, the insider/funding checks, and how to price a "becoming" stock against a dated catalyst. Written to rerun on the next strategic material.
2026-JUN-25 · Prinsights (Substack) · Nomi Prins (ex-Goldman Sachs MD; Prinsights Global) · ↗ Read · full analysis · article text
How to read this page: each insight is a method — the screen that narrows a squeeze down to one name, the checks that confirm it, and what to watch when re-running it on another critical metal. The boxed line shows how it played out for Almonty (ALM). (Written newsletter — "read" links open the source post; no timestamps.)

1. Screen for the integrated mine-and-process producer outside the dominant supplier

The repeatable method
  1. Start from the bottleneck (processing, not mining) and require both steps in one company outside the dominant supplier: a miner that ships concentrate to China to be refined "has not detached from China's grip."
  2. Rank survivors by scale of integrated capacity — the producer whose own output can move the ex-China balance is the one that captures the scarcity rent.
  3. Reject pure miners and pure processors; the thesis only pays if the company controls the whole chain it sells from.
Here: Almonty is "the largest Western-aligned tungsten producer and the only major one that owns both mining and processing outside China" — Sangdong's Phase 2 alone (2027) is ~40% of non-Chinese global supply.
Watch for

2. Require a locked offtake at a hard floor that matches the coming legal rule

The repeatable method
  1. Look for a binding offtake with a defined end-buyer and volume, ideally at a hard floor price (no cap) — that converts a commodity producer into a contracted-revenue one and de-risks the squeeze thesis.
  2. Check the offtake counterparty is on the right side of the dated legal forcing function (the sourcing ban), so the contract is the compliance solution buyers must lock in early.
  3. Treat "contractors locking in compliant supply now" as the demand pull that front-runs the rule's effective date.
Here: a May 2025 binding deal with Tungsten Parts Wyoming — ≥40 t/month of tungsten oxide for U.S. defense at a hard floor, no cap — fitting the Jan-1-2027 DFARS ban (China/Russia/Iran/N. Korea barred from the whole chain) "exactly."
Watch for

3. Confirm insider alignment and a funded balance sheet before the build pays off

The repeatable method
  1. For a pre-cash-flow ramp story, verify management has skin in the game (large insider ownership, recent open-market buying) and relevant policy/operational pedigree on the board — alignment matters most when results are years out.
  2. Confirm the project is fully funded through its value-creating phase so the thesis doesn't depend on raising into a weak tape.
  3. Read the income statement past the headline: strip non-cash charges (warrant/derivative revaluations) to see whether operations are already profitable.
Here: CEO Lewis Black owns ~8M shares (>$130M), an active buyer in early 2025; board added Gen. Perna (Warp Speed logistics) and Alan Estevez (ex-Commerce export-control architect). ~$259.9M cash funds Sangdong Phase 2; the Q1 net loss was non-cash ($8.4M warrant revaluation) while EBITDA was +$6.1M.
Watch for

4. Price a "becoming" stock against the dated catalyst — and set a buy-up-to discipline

The repeatable method
  1. Accept that a ramp name trades on what the asset becomes, not trailing revenue (here ~$4.6B cap on ~$100M revenue) — so anchor valuation to the Phase-2 output and the policy re-rating, not the current multiple.
  2. Use a discrete dated catalyst (a Section 232 report, an index inclusion) to time the thesis, and treat a sharp pullback ahead of it as the entry.
  3. Impose a buy-up-to ceiling so conviction doesn't turn into chasing — and size for the named risks (execution, dilution, single-commodity, price volatility).
Here: stock ~$16.46 after a ~30% pullback from its ~$23.50 April peak, with Section 232 (July 13), Russell 1000 inclusion (June 29) and Sangdong Phase 2 (2027) ahead — buy up to $22.
Watch for

Methods distilled from the Prinsights Pulse Premium post (text in transcript.txt) for personal study. Not investment advice. © Nomi Prins / Prinsights for source material.